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Abstract
Objective-To compare the fatal toxicities of
antidepressant drugs in 1987-92.
Design-Retrospective epidemiological review of
prescription data of the Department of Health,
Scottish Office Home and Health Department, and
Welsh Health Common Services Authority (exclud-
ing data from most private general practices and
most hospitals), and mortality data from the Office
of Population Censuses and Surveys and General
Register Office in Scotland.
Setting-General practice, England, Scotland,
and Wales.
Main outcome measures-Deaths per million pre-
scriptions and deaths per defined daily dose.
Results-816% (1310/1606) of deaths from anti-
depressant overdose were due to two drugs, amitrip-
tyline and dothiepin. The overall average of deaths
per million prescriptions was 30-1. The overall
rate for tricyclic drugs was 34-14 (95% confidence
interval 32*47 to 38-86; P<0-001), monoamine
oxidase inhibitors 13*48 (6-93 to 22-19; P<0.001),
atypical drugs 6-19 (404 to 8*80; P<0-001), and
selective serotonin reuptake inhibitors 2.02 (0.64 to
4*17; P<0-001). The numbers of deaths- per million
prescriptions of amoxapine, dothiepin, and ami-
triptyline were significantly higher than expected,
while nine drugs had a significantly lower number of
deaths per million prescriptions than expected.
Analysis of deaths per defined daily dose showed a
similar pattern.
Conclusions-Safety in overdose should be con-
sidered in risk-benefit and cost-benefit consider-
ations of antidepressants. A switch in prescribing,
from drugs with a high number ofdeaths per million
prescriptions to drugs with a low number, could
reduce the numbers of deaths from overdose.
Although this form of suicide prevention can be
implemented easily and immediately, its intro-
duction needs to be considered against the higher
costs ofsome ofthe newer drugs.
Introduction
While little demonstrable difference exists between
antidepressants in terms of efficacy,' toxicity in over-
dose varies widely.' We compared the fatal toxicities of
antidepressants currently available in Britain individu-
ally and by group during 1987-92, during which time
the selective serotonin reuptake inhibitors were intro-
duced.
Methods
Antidepressants were assigned to four classes:
monoamine oxidase inhibitors, tricyclic antidepres-
sants, selective serotonin reuptake inhibitors, and the
so called "atypical"3 antidepressants. We obtained
numbers of deaths in England, Wales, and Scotland
due to acute poisoning by a single antidepressant.4'
The statistics and research division of the Department
of Health supplied data on the number of anti-
depressant prescriptions for general medical practices
within the NHS for England, Wales, and Scotland for
1987-9 and for England for 1990-2; for 1990-2 the
Scottish data were provided by the Scottish Office
Home and Health Department and the Welsh data
by the Welsh Health Common Services Authority.
Private general practice and most hospitals were
excluded; figures for 1991 and 1992 include dispensing
practices. About three quarters of all drug prescrip-
tions are written by general practitioners.6 7 Most
patients with psychiatric disorders, however, are
treated by general practitioners rather than by psy-
chiatristsS" (90% to 98% ofdepressed patients"`). The
exclusion of hospital prescriptions from our analysis
should not, therefore, appreciably affect the outcome
ofthis study.
We calculated the number of deaths per million
prescriptions during the six years for all the drugs
taken together; for each of the four groups of anti-
depressants; and for each drug individually. The X2 test
was applied to the groups of antidepressants. The
expected numbers of deaths are given for the indi-
vidual drugs, with Fisher's exact test (one tailed)
applied to the data. Confidence limits are calculated as
x± 196 SD(x).
Using the prescribed data, we considered each
preparation of each drug analysed, multiplied the
strength of the preparation by the quantity prescribed,
and divided this by the defined daily dose values
(obtained from the World Health Organisation)."'3
We calculated the number of defined daily doses per
prescription for each drug and the number of deaths
per million defined daily doses prescribed.
Results
The mean annual number of deaths due to overdose
with a single antidepressant over the six years was
268 (range 238 to 288). The tricyclic drugs were
implicated in most deaths (table I), with two drugs-
amitriptyline and dothiepin-accounting for 81-6% of
all deaths. Tables II and III show the figures for
mortality and data for prescriptions for deaths per
million prescriptions for the four groups of drugs for
the six years. The tricyclic antidepressants as a group
TABLE i-Mean yearly numbers of deaths from tricyclic and other
antidepressants, 1987-92
Death from Death from
tricyclic non-tricyclic
Cause of death drugs drugs
Suicide with single antidepressant 150 4
Suicide with more than one substance, including
antidepressants 240 10
Overdose with single antidepressant 260 12
Overdose with more than one substance,
including antidepressants 424 24
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had a significantly higher number of deaths per million
prescriptions than expected compared with all the
antidepressants taken together (P < 000 1). The mono-
amine oxidase inhibitors as a group had a lower than
expected number of deaths per million prescriptions
(P< 000 1). The groups of atypical antidepressants and
selective serotonin reuptake inhibitors each had the
lowest number of deaths per million prescriptions
(P<0-001). Tables IV and V list each drug in each
group with its number of deaths per million prescrip-
tions, which is used to rank them within groups, and
shows that three of the tricyclic agents (dothiepin,
amitriptyline, and amoxapine) had a significantly
higher number of deaths per million prescriptions than
expected. A further three drugs from this group
(lofepramine, clomipramine and trimipramine) had
a significantly lower number of deaths per million
prescriptions than expected when compared with all
antidepressants. One monoamine oxidase inhibitor
(phenelzine) had a significantly lower number of
deaths per million prescriptions. Two of the atypical
TABLE iI-Fatal poisonings and deaths per million prescriptions for deaths from single antidepressant, by
groups ofdrug. Values in parentheses are 95% confidence intervals
No of
Observed Expected prescriptions
deaths deaths (millions) Deaths per million
Antidepressant 1987-92 1987-92 1987-92 X2value prescriptions 1987-92
Tricyclicdrugs 1563 1378 45-78 24-80 4 14 (34-47 to 35-86)*
Monoamine oxidase inhibitors 12 27 0-89 8-17 13-48 (6-93 to 2219)*
Atypical drugs 26 126 4-20 79-78 6-19 (4 04 to 8 80)*
Selective serotonin reuptake inhibitors 5 75 2-48 64-99 2-02 (0-64 to 4-17)
All antidepressants 1606 1606 53-35 30-10
*P< 0-05 P< 0-001 (difference from all by X2 test).
TABLE III-Fatal poisonings and deaths per million defined daily doses for deaths from single
antidepressants, by groups ofdrug. Values in parentheses are 95% confidence intervals
Mean
Observed Expected defined daily Deaths per million
deaths deaths dose (mg) defined daily doses
Antidepressant 1987-92 1987-92 1987-92 X2value 1987-92
Tricyclicdrugs 1563 1346 94 34-98 16-63 (1-36to 1-50)*
Monoamine oxidase inhibitors 12 41 28 20-51 0 43 (0-19 to 0 60)*
Atypical drugs 26 62 165 20-90 0-16 (034 to 0 74)*
Selective serotonin reuptake inhibitors 5 56 66 46-45 0-08 (0-03 to 0 23)
All antidepressants 1606 1606 89 1-26
*P 0-001 (difference from all by X2 test).
TABLE IV-Fatal poisonings and deaths per million prescriptions for deaths from single antidepressants, by
individual antidepressant. Values in parentheses are 95% confidence intervals
Expected deaths
Year introduced Observed deaths 1987-92 from Deaths per million
Antidepressant to Britain 1987-92 mean of all prescriptions 1987-92
Tricyclic drugs:
Amoxapine 1989 13 2 157-18 (83-35 to 254 23)***
Desipramine 1963 3 1 75-76 (14-28 to 185-74)
Nortriptyline 1963 19 11 51-77 (31-11 to77-67)
Dothiepin 1969 801 504 47-86 (44-60 to 51-23)***
Amitriptyline 1961 509 394 38-94 (35-63 to42.39)*
Imipramine 1959 111 106 31-54 (25-95 to 37 68)
Doxepin 1969 37 46 23-99 (16-89 to 32 35)
Trimipramine 1966 34 73 13-93 (9-64to 19-01)***
Clopramine 1970 26 108 7-26 (4 74 to 10-32)***
Lofepramine 1983 10 125 2-42 (1-15to4-14)***
Protriptyline 1966 0 4 0 00
Iprindole 1968 0 1 0 00
Butriptyline 1975 0 0 0 00
Monoamine oxidase inhibitors:
Tranylcypromine 1960 8 9 27-87 (11-90 to 50 54)
Phenelzine 1959 4 15 7-86 (2-04 to 17-45)
Iproniazid 1958 0 0 0 00
Isocarboxazid 1960 0 3 0 00
Atypical drugs:
Viloxazine 1974 1 0 63-17 (0 03 to 247 66)
Maprotiline 1974 6 11 16-22(5-84 to 31-80)***
Trazodone 1980 7 27 7 83 (3-10to 14.70)***
Mianserin 1976 12 88 4-11 (2-11 to6-76)***
Selective serotonin reuptake inhibitors:
Sertraline 1990 1 5 6-23 (0.00 to 24.43)
Paroxetine 1991 1 12 2-60 (0 00 to 10 18)**
Fluvoxamine 1987 2 13 4-78 (0 45 to 13-71)**
Fluoxetine 1989 1 46 0-66 (0 00 to 2 58)***
All antidepressants 1606 30-10
*P<0 05,**P<0 01,***P<0 001 (differencefromallbyFisher'sexacttest).
Total expected deaths differ from total observed owing to rounding.
drugs (mianserin and trazodone) had a significantly
lower number of deaths per million prescriptions.
Three of the selective serotonin reuptake inhibitors
(fluoxetine, fluvoxamine, and paroxetine) had a lower
number of deaths per million prescriptions. No deaths
were recorded for five drugs, all of which had low
prescription figures (table III). Calculation of data with
defined daily doses showed a pattern that was broadly
similar to the data derived from deaths per million
prescriptions.
Discussion
The atypical antidepressants form a heterogeneous
group of drugs, while the other antidepressants fall
into three pharmacologically homogeneous groups.
The selective serotonin reuptake inhibitors share a
common mechanism of action, despite their remark-
ably differing chemical structures (fluvoxamine is
a monocyclic agent, fluoxetine a bicyclic agent, sertra-
line a naphthylamine derivative, and paroxetine a
phenyl piperidine derivative). They also had the lowest
toxicity in overdose of the groups of drugs studied
here. This accords with clinical experience.'"'7 The
numbers of deaths per million prescriptions of anti-
depressants have been shown to be inversely related to
their serotonin reuptake inhibition activity,'8 but this
relation may be coincidental with their structural
properties.
Shortcomings of a study of this nature include
systematic error in prescription or mortality data, or
both; confounding by prescriber biases or patient
biases-such as, an inability to distinguish between the
use of "first line" and "second line" drugs-or both
biases; and the fact that no allowance was made for
prescribing for indications other than those of concern
to the study. These factors, however, are unlikely to
affect the conclusions of our study as most biases run in
favour of the tricyclic drugs, which are more widely
used as first line drugs.'9 It is also possible that selective
serotonin reuptake inhibitors are being prescribed to
patients at greater risk of overdose.20 These drugs may
also have a different role from tricyclic drugs in
patients with depression resistant to treatment-for
example, paroxetine3-or with suicidal thoughts-for
example, fluoxetine ' and fluvoxamine.55 Our data thus
provide a useful guide to the relative toxicities of drugs
and an indication of the needs of prescribing policy and
correlate with the results of median lethal dose in
animals.23 Our data also agree with alternative indices
based on deaths per million standard quantity units or
deaths per thousand kilograms of drug prescribed.24
The use of data on defined daily dose is gaining
popularity internationally, mainly because defined
daily doses provide a standardised technical measure of
drug use that is not influenced by strength of dosage
form. The dose is an assumed average daily dose for the
main indication of a drug as determined by the Nordic
Council on Medicines,'3 and this causes problems in its
use in a study like ours. Problems include variation in
the number of prescriptions that depressed patients
have each year; discontinuation or non-compliance,
especially for tricyclic drugs,25 which increases the
apparent market share of other antidepressants; and
prescription of drugs at doses below or above the
defined daily dose. These factors might be expected to
bias toxicity data in favour of the tricyclic drugs,26 but
our analysis shows a strong correlation in the ranking
of the two indices.
The differing toxicities of antidepressants in over-
dose should be considered against the wider issue of
costs. The selective serotonin reuptake inhibitors are
relatively expensive and are generally prescribed at
effective daily doses, which can hardly be reduced to
save on costs. Ironically, it is the cheaper, tricyclic
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TABLE v-Fatal poisonings and deaths per million defined daily doses for deaths from single antidepressants,
by individual antidepressant. Values in parentheses are 95% confidence intervals
Observed Expected deaths Deaths per million defined
Defined deaths 1987-92 daily doses
Antidepressant daily dose 1987-92 for mean of all 1987-92
Tricyclic drugs:
Amoxapine 150 13 2 6-22 (4-13 to 12-6)***
Desipramine 100 3 1 2-79 (0-55 to 7-15)
Nortriptyline 75 19 10 2-28 (1-38 to 3 44)**
Amitriptyline 75 509 394 1-64 (1-46 to 1-74)*
Dothiepin 75 801 648 1-54 (1-42 to 1-63)***
Imipramine 100 111 94 1-47 (1-2 to 1-74)
Doxepin 100 37 33 1-4 (0-98 to 1-88)
Trimipramine 150 34 38 1 1 (0-76 to 1-49)
Clomipramine 100 26 84 0-38 (0-25 to 0 54)***
Lofepramine 105 10 196 0-08 (0-03 to 01 1)***
Protriptyline 30 0 3 0
Iprindole 90 0 0 0
Butriptyline 75 0 0 0
Monoamine oxidase inhibitors:
Tranylcypromine 10 8 22 0 54 (0-19 to 0 8)**
Phenelzine 60 4 14 0-38 (0-09 to 0Q79)*
Iproniazid 0 0 0
Isocarboxazid 15 0 6 0
Atypical drugs:
Viloxazine 200 1 0 3 03 (Oto 12-27)
Maprotiline 100 6 11 0 77 (0-25 to 1-39)
Trazodone 300 7 16 0-6 (0-21 to 0 99)
Mianserin 60 12 70 0-2 (011 to 0 35)***
Selective serotonin reuptake inhibitors:
Fluvoxamine 150 2 1 1 0-19 (0-02 to 0 66)*
Sertraline 75 1 6 0-13 (OtoO-81)
Paroxetine 20 1 19 0 04 (O to 0 26)***
Fluoxetine 20 1 66 0-02 (O to 0 07)***
All antidepressants 89 1606
*P<005,**P<001, ***P<0001 (difference from all by Fisher's exact test).
Total expected deaths differ from total observed owing to rounding.
antidepressants that are more likely to be prescribed in
subtherapeutic doses'027 to avoid adverse effects.'02728
The widely perceived cost advantage of tricyclic drugs
is based almost entirely on market price alone29; many
other factors influence the cost to the NHS, and
virtually all models of clinical practice give the selective
serotonin reuptake inhibitors a cost advantage.29-' One
cost effectiveness study estimated that £19 000-173 000
per life year was gained from deaths from overdose
prevented by a switch in routine first line use
from tricyclic drugs to selective serotonin reuptake
inhibitors.'2 This finding rested, however, on the
assumption that the only differences between the
different groups of antidepressant drugs lay in the
market prices of the drugs and the numbers of deaths
from overdose. Many other factors would need to be
considered for a valid comparison. Overdose itself has
cost implications, regardless of whether death results.
The tricyclic drugs are more likely to lead to medical
Key messages
* Overdose with an antidepressant such as
amitriptyline or dothiepin could lead to severe
toxicity and could be fatal
* Antidepressant drugs such as the selective
serotonin reuptake inhibitors and lofepramine
have low toxicity in overdose
* Deaths from overdose can be prevented
by switching prescribing from older, tricyclic
drugs; such a move may contribute to govern-
ment targets for reducing suicide
* Choice of a first line antidepressant should be
based on several factors, including adverse effect
profile, compliance, overdose safety, and cost,
and the antidepressant should be appropriate to
the patient and his or her clinical condition
* Patients with evidence of suicidal ideation
should be given special consideration-admis-
sion to hospital may be indicated
complications and admissions to intensive therapy
units.3
The British Association for Psychopharmacology
concluded that the newer antidepressants have real
advantages over the older ones in terms of safety and
tolerability when given in an effective dose.34 Low
toxicity in overdose is an important consideration in
the drug treatment of depressed patients. Although it
can be argued that a failed suicide attempt may only
delay the ultimate outcome, it is widely accepted that
a suicide attempt is a poor predictor of further
attempts35; about 10% of those who fail to kill them-
selves with acute overdose go on to successful suicide."
Furthermore, a drug overdose might bring the patient
under closer medical supervision and lead to a better
outcome to the depressive episode. While the present
study shows that fatal overdose is an important
problem, untreated depression may be even more
important.26
As a result of the "Defeat Depression" campaign by
the Royal Colleges of Psychiatrists and General Prac-
titioners the diagnosis of depression may increase over
the next few years. Wider use of drugs with a high
number of deaths per million prescriptions could lead
to an increase in the number of successful suicides from
antidepressant overdose. Conversely, wider use of
drugs with a low number of deaths per million
prescriptions would make a contribution towards the
government's targets for the year 2000 of reducing the
number of suicides.
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Is the three year breast screening interval too long? Occurrence of
interval cancers in NHS breast screening programme's north western
region
Ciaran B J Woodman, Anthony G Threlfall, Caroline RM Boggis, Pat Prior
Abstract
Objective-To report the detection rate of interval
cancers in women screened by the NHS breast
screening programme.
Design-Detection of interval cancers by
computer linkage of records held by the screening
centres in the North Western Regional Health
Authority with breast cancer registrations at the
regional cancer registry.
Setting-North Western Regional Health
Authority.
Subjects-137 421 women screened between 1
March 1988 and 31 March 1992 who had a negative
screening result.
Results-297 invasive interval cancers were
detected. The rate of detection of interval cancers
expressed as a proportion of the underlying inci-
dence was 31% in the first 12 months after screening,
52% between 12 and 24 months, and 82% between 24
and 36 months.
Conclusion-The incidence of interval cancers in
the third year after breast screening approaches that
which would have been expected in the absence of
screening and suggests that the three year interval
between screens is too long.
Introduction
Trials of mass screening show that there is potential
for reducing mortality from breast cancer in women.'4
Preliminary results from the NHS breast screening
programme have been considered satisfactory5 but no
information has been reported on the incidence of
interval cancers. The incidence of these cancers must
be kept comparatively low if the screening programme
is to be successful.6 We report the incidence of interval
cancers in women screened by the programme in the
North Western region.
ORGANISATION OF SCREENING IN NORTH WEST
The NHS breast screening programme began
screening women in the North Western region in
March 1988. Women on family health services
authority registers aged 50-64 are invited to be
screened by single view mammography every three
years. There are five screening centres in the North
Western region; two began screening in March 1988,
the third began in June 1988, the fourth in January
1990, and the fifth in June 1991. These centres cover
estimated target populations of about 49 200, 49 900,
127 400, 46600, and 36800 respectively. The uptake
rate in the first screening round estimated from Korner
returns form KC62 was 73%, and the cancer detection
rate was 5 9 per 1000 women screened.
Subjects and methods
The study population included all women in the
North Western Regional Health Authority area aged
50-64 routinely screened for the first time as part of the
NHS breast screening programme by the region's first
four breast screening centres between 1 April 1988 and
31 March 1992.
Definition of interval cancer-A woman was con-
sidered to have an interval cancer if there was
histological confirmation of a primary breast cancer
within three years of her last negative screening
assessment. We included women presenting with
symptoms while on early recall but excluded women
presenting with in situ disease.
Identification of interval cancers-Interval cancers
were identified by linking records held by the screen-
ing centres and the North West Regional Cancer
Registry. The registry has been population based since
1962 and uses multiple sources of registration to
ascertain all cancers occurring in residents of the North
Western region. The name, date of birth, and screen-
ing history of all women screened after 1 April 1988
were down loaded from the breast screening centres'
computer systems. Name and date of birth were used
to computer match screened women with registrations
of primary breast cancer diagnosed after the start of
the screening programme. Positive matches were
confirmed by using the woman's address. Women
with screen detected cancers were excluded. For the
remaining women the date of the last negative screen
and the date of the histological diagnosis of cancer were
compared and probable interval cancers identified.
The screening records of these women were examined
to verify that they were interval cancers. In order to
minimise delay in cancer registration a policy to "fast
track" breast cancer registrations was introduced.
However, a few interval cancers that had been reported
to the screening centres direct were not registered at
the cancer registry but are included in the analysis. In
all but three cases this was due to the inevitable delay
before a cancer is registered.
Statistical methods-The rate of detection of interval
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